A study testing nivolumab with relatlimab for melanoma that has spread to the brain
Original title: Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study in people, so it is still being tested.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether two immune drugs, given together, can help control melanoma that has spread to the brain.
Who this trial is for. This trial is for people with melanoma that has spread to the brain. It is testing nivolumab given together with relatlimab, and how safe that pair of drugs is.
Where it stands. This trial has not reported results. It is measuring whether the two drugs together help control melanoma in the brain. It is also measuring safety and side effects. The answers are not in yet.
What this means, and what it doesn't
What it could mean: If you have melanoma that has spread to the brain, this is one study you could ask your care team about. They know your case and can tell you if it is worth looking into. Whether anyone can join is decided by the trial team.
What it doesn't mean: This does not mean the two drugs work. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that you will be helped. It is not a promise of a cure.
Source: ClinicalTrials.gov, July 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.